Your browser doesn't support javascript.
Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies.
McCaw, Zachary R; Tian, Lu; Kim, Dae Hyun; Localio, A Russell; Wei, Lee-Jen.
  • McCaw ZR; Google, Mountain View, California, USA.
  • Tian L; Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
  • Kim DH; Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts, USA.
  • Localio AR; Division of Biostatistics, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Wei LJ; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Clin Infect Dis ; 72(11): e887-e889, 2021 06 01.
Article in English | MEDLINE | ID: covidwho-1249295
ABSTRACT
For survival analysis in comparative coronavirus disease 2019 trials, the routinely used hazard ratio may not provide a meaningful summary of the treatment effect. The mean survival time difference/ratio is an intuitive, assumption-free alternative. However, for short-term studies, landmark mortality rate differences/ratios are more clinically relevant and should be formally analyzed and reported.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid